Mostrar el registro sencillo del ítem

Artículo

dc.creatorGallego Durán, Rocíoes
dc.creatorMontero-Vallejo, Rocíoes
dc.creatorMaya Miles, Douglases
dc.creatorLucena, Anaes
dc.creatorMartin, Franzes
dc.creatorAmpuero Herrojo, Javieres
dc.creatorRomero Gómez, Manueles
dc.date.accessioned2022-11-24T17:12:18Z
dc.date.available2022-11-24T17:12:18Z
dc.date.issued2021-11-24
dc.identifier.citationGallego Durán, R., Montero-Vallejo, R., Maya Miles, D., Lucena, A., Martin, F., Ampuero Herrojo, J. y Romero Gómez, M. (2021). Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Frontiers in Immunology, 12, 667354. https://doi.org/10.3389/fimmu.2021.667354.
dc.identifier.issn1664-3224es
dc.identifier.urihttps://hdl.handle.net/11441/139766
dc.description.abstractMetabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has displaced viral hepatitis as the main cause of severe forms of hepatic diseases, although the onset and transition of MAFLD stages still remains unclear. Nevertheless, innate and adaptive immune responses seem to play an essential role in the establishment and further progression of this disease. The immune system is responsible of safeguard and preserves organs and systems function, and might be altered under different stimuli. Thus, the liver suffers from metabolic and immune changes leading to different injuries and loss of function. It has been stablished that cell-cell crosstalk is a key process in the hepatic homeostasis maintenance. There is mounting evidence suggesting that MAFLD pathogenesis is determined by a complex interaction of environmental, genetic and host factors that leads to a full plethora of outcomes. Therefore, herein we will revisit and discuss the interplay between immune mechanisms and MAFLD, highlighting the potential role of immunological markers in an attempt to clarify its relationship.es
dc.formatapplication/pdfes
dc.format.extent11 p.es
dc.language.isoenges
dc.publisherFrontiers Mediaes
dc.relation.ispartofFrontiers in Immunology, 12, 667354.
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectNAFLDes
dc.subjectNASHes
dc.subjectimmunologyes
dc.subjectfibrosises
dc.subjectbiomarkerses
dc.titleAnalysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseaseses
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDPC-0148-2016-0148es
dc.relation.projectIDPE-0451 -2018es
dc.relation.projectIDAGL2017-86927-Res
dc.relation.projectIDPI16/01842es
dc.relation.projectIDPI19/01404es
dc.relation.projectIDPI19/00589es
dc.relation.projectIDIFI18/00041es
dc.relation.projectIDCD18/00126es
dc.relation.publisherversionFrontiers Mediaes
dc.identifier.doi10.3389/fimmu.2021.667354es
dc.journaltitleFrontiers in Immunologyes
dc.publication.volumen12es
dc.publication.initialPage667354es
dc.contributor.funderConsejería de Salud. Junta de Andalucía PC-0148-2016-0148es
dc.contributor.funderFondo Europeo de Desarrollo Regional (FEDER) en colaboración con la Consejería de Salud de la Junta de Andalucía PE-0451 -2018es
dc.contributor.funderMinisterio de Economía y Competitividad AGL2017-86927-Res
dc.contributor.funderInstituto de Salud Carlos III (PI16/01842, PI19/01404, PI19/00589, IFI18/00041 y CD18/00126)es

FicherosTamañoFormatoVerDescripción
Analysis of Common Pathways and ...994.9KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Atribución 4.0 Internacional